Your Current Position: NEWS
-
【Company News】 ConVerd's Oncolytic Vaccinia Virus hV01 Completed First Patient Dosing in Its First Phase IIa Clinical Study2025-04-16On April 15, 2025, The first Phase IIa clinical study of hV01, ConVerd's first oncolytic vaccinia virus product, successfully completed its first patient dosing, with the subject in good condition.
-
【Company News】 ConVerd's First Oncolytic Vaccinia Virus Product hV01 Advances to Phase II Clinical Study2025-02-07October 29, 2024 – ConVerd's first oncolytic vaccinia virus product, hV01, has received approval from the Medical Ethics Committee of Zhejiang Provincial People's Hospital, marking the initiation of its Phase IIa clinical study.
-
【Company News】 Hangzhou Venture Capital Association Visited ConVerd in 2024 Unicorn Company Tour Series2024-06-28June 27, 2024 – ConVerd Pharmaceuticals recently welcomed a delegation from the Hangzhou Venture Capital Association (HVCA) under the guidance of the Hangzhou Science and Technology Bureau.
-
【Company News】 ConVerd's First Oncolytic Vaccinia Virus Product hV01 Completes First Patient Dosing in Clinical Trial2023-07-17On July 14，2023，The Phase I clinical study of hV01 has successfully completed its first patient dosing at the lead clinical site, Fudan University Shanghai Cancer Center, with the subject in good condition.
-
【Company News】 ConVerd's first oncolytic vaccinia virus product V01 Obtained Clinical Trial Approval2023-03-31On March 28, 2023, ConVerd’s first oncolytic vaccinia virus product, hV01, received implicit approval for clinical trials from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).
-
2022-12-22On Dec. 21, 2022, the Investigational New Drug (IND) Application of V01, the first oncolytic vaccinia virus product independently innovated by Converd, was accepted by Center For Drug Evaluation, NMPA.
-
【Company News】 Latest clinical findings of the ConVerd's subsidiary self-develped NKG2D-CAR-NK published in Molecular Therapy2019-09-21The latest results of a NKG2D-CAR-NK's clinical stuy, conducted by ConVerd's subsidiary and a team led by Hu Xv who is the president of the 3rd hospital of Guangzhou Medical University, were publishe in the journal, Molecular Therapy.
-
2019-04-12Recently, Hangzhou ConVerd Co., Ltd. made its debut at the 2019 Annual Meeting of the American Association for Cancer Research (AACR Annual Meeting 2019)
-
On Mar.18, 2019, Cold Genesys, an American company developing a form of cancer immunotherapy using genetically engineered viruses, has closed a $22 million round of funding.
-
【Company News】 Promote independent scientific and technological innovation and protect intellectual property rights -- the medical bioinventory review department of Patent Examination Cooperation (Beijing) Center of the Patent Office, CNIPA2018-11-17On November 14, 2018, a group of seven people, from Patent examination Examination of the state Cooperation (Beijing) Center of the Patent Office, CNIPA， came to Hangzhou Future Sci-Tech City